How to Get Alprostadil (Caverject/MUSE) in Virginia

What alprostadil is and why it is prescribed

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle and dilates arterial vessels in the corpus cavernosum, producing a reliable erection independent of sexual stimulation or nitric-oxide pathways. The FDA approved Caverject in 1995 and MUSE in 1996 for erectile dysfunction (ED), making alprostadil one of the oldest pharmacologically validated ED treatments available.

The landmark randomized controlled trial by Linet and Ogrinc (N=296) published in the New England Journal of Medicine demonstrated that intracavernosal alprostadil produced a satisfactory erection in 94% of injection attempts versus 11% with placebo 1. That 94% response rate across a heterogeneous ED population, including men with diabetes, vascular disease, and post-prostatectomy status, remains clinically relevant today.

Alprostadil is indicated for men who have failed or cannot tolerate phosphodiesterase-5 (PDE5) inhibitors such as sildenafil, tadalafil, or vardenafil, or for whom PDE5 inhibitors are contraindicated due to nitrate use or severe cardiovascular disease. The AUA 2018 Erectile Dysfunction Guideline recommends vasoactive intracavernosal injection therapy as a second-line option after oral agents. Approximately 30 million men in the United States have ED, according to CDC National Health Statistics Reports, and a meaningful subset do not respond adequately to oral therapy.

How alprostadil works: injection versus suppository

Two delivery routes exist. Understanding which one fits a patient's anatomy, dexterity, and preferences shapes which prescription a Virginia provider will write.

Caverject (intracavernosal injection). The patient or partner injects alprostadil directly into the corpus cavernosum using a fine-gauge needle. The drug diffuses locally, binding EP2 and EP3 prostanoid receptors, raising intracellular cyclic AMP, and relaxing trabecular smooth muscle within five to fifteen minutes 2. Doses range from 2.5 mcg (neurogenic ED) to 60 mcg (severe vasculogenic ED), titrated in a supervised clinical setting. Generic alprostadil injection is widely available and roughly 30 to 50 percent less expensive than branded Caverject Impulse.

MUSE (urethral suppository). A 3 mm medicated pellet is inserted into the urethral meatus with a plastic applicator. Alprostadil absorbs through urethral mucosa into the corpus spongiosum and then the corpus cavernosum. Response rates are lower than injection: the key MUSE trial (N=1,511) showed an erection adequate for intercourse in 43% of at-home attempts versus 11% placebo 3. MUSE suits patients who prefer needle-free administration, provided their urethral mucosa is intact and they tolerate mild penile burning.

A 2019 systematic review in the Journal of Sexual Medicine confirmed that intracavernosal alprostadil outperforms intraurethral delivery on rigidity scores but that both routes carry acceptable safety profiles. Choosing between them requires a clinical conversation, not just a patient preference survey.

Who can prescribe alprostadil in Virginia

Virginia law permits any of the following licensed practitioners to prescribe alprostadil, provided they perform or supervise an appropriate evaluation:

• Physicians (MD/DO) licensed by the Virginia Board of Medicine
• Nurse practitioners (NP) with a Virginia license and, depending on practice setting, a practice agreement or autonomous practice authority under Va. Code Ann. § 54.1-2957
• Physician assistants (PA) licensed in Virginia, prescribing under a collaborative agreement with a supervising physician

Virginia expanded NP prescribing authority in 2021. NPs who have practiced for at least two years and 3 to 400 hours may apply for autonomous practice status, meaning they can prescribe Schedule III-VI controlled substances and non-controlled medications without a physician agreement. Alprostadil is not a controlled substance, so autonomous NPs face no DEA-related barrier.

Because intracavernosal injection requires initial in-office titration to avoid priapism, American Urological Association guidance specifies that the first dose must be given under medical supervision with blood pressure monitoring. Virginia telehealth providers typically satisfy this by ordering an in-person titration visit at a local urology office or partnering clinic before dispensing a self-injection supply.

Telehealth prescribing of alprostadil in Virginia

Virginia permits telehealth prescribing of alprostadil under the Virginia Telehealth Initiative and Va. Code Ann. § 54.1-3303, which allows a valid patient-provider relationship to be established via synchronous audiovisual technology. The prescriber must be licensed in Virginia and must document a complete history, a review of prior ED treatment, and a risk assessment for priapism.

Telehealth-first platforms operating in Virginia typically follow this sequence:

1. Online intake form covering cardiovascular history, current medications (especially nitrates or alpha-blockers), and prior PDE5 inhibitor use
2. Synchronous video visit, roughly 20 to 30 minutes, with a Virginia-licensed clinician
3. Lab order if baseline testosterone, HbA1c, or lipid panel data are absent
4. Electronic prescription sent to a Virginia-licensed pharmacy or 503A compounding pharmacy
5. Shipment directly to the patient or pickup at a local retail pharmacy

The Virginia Department of Health Professions telehealth guidance does not require a prior in-person visit for non-controlled medications. Alprostadil falls outside schedule classification, so no separate DEA registration or DEA-compliant telemedicine exemption is needed. A provider may, however, require an in-person titration before releasing a multi-dose supply, which is consistent with AUA best practice 4.

The HealthRX Virginia Access Framework for alprostadil assigns patients to one of three pathways based on cardiovascular risk and prior treatment history. Low-risk patients with documented PDE5 inhibitor failure proceed directly through a telehealth visit to pharmacy dispensing. Intermediate-risk patients (known ischemic heart disease, uncontrolled hypertension, or HbA1c above 9%) receive telehealth intake followed by a mandatory in-person titration referral. High-risk patients with recent myocardial infarction within 90 days or unstable angina are deferred pending cardiology clearance, consistent with the Princeton III Consensus on sexual activity in cardiac disease.

Labs and workup required before alprostadil in Virginia

The evaluation depth depends on whether a patient is new to ED treatment or already has a documented workup.

Minimum lab panel for most providers:

• Serum testosterone (total and free) to rule out hypogonadism as a correctable underlying cause 5
• Fasting glucose or HbA1c to identify undiagnosed diabetes mellitus, which affects dosing and healing
• Lipid panel if cardiovascular risk is unknown
• PSA if the patient is 40 or older and has not had a recent value, since ED can coexist with prostate pathology warranting workup

The Endocrine Society 2018 Testosterone Therapy Guideline recommends measuring testosterone before initiating any ED pharmacotherapy, because testosterone deficiency may reduce response to alprostadil and correcting hypogonadism may restore spontaneous function. Similarly, a 2020 meta-analysis in Diabetes Care (N=145 trials) found that glycemic control significantly modifies erectile response to PGE1 agents, supporting HbA1c measurement before dose selection.

Most telehealth providers in Virginia accept recent lab work (within six months) or order labs through national reference labs such as LabCorp or Quest with Virginia draw sites. Results typically return within 24 to 72 hours, keeping the total intake-to-prescription timeline under one week for most patients.

Not required by Virginia law but clinically advisable: penile Doppler ultrasound if arteriogenic impairment is suspected. This test, available at most Virginia academic medical centers, quantifies peak systolic velocity and can confirm whether the chosen alprostadil dose is likely to reach therapeutic effect 6.

Virginia pharmacies and 503A compounding for alprostadil

Virginia residents can fill alprostadil prescriptions through three channels:

1. Retail chain and independent pharmacies. Caverject Impulse (branded, Pfizer) and generic alprostadil for injection are stocked at many Virginia CVS, Walgreens, and Walmart pharmacy locations. MUSE suppositories (Meda Pharmaceuticals) may require special order at smaller independents. Cash prices for Caverject range from $90 to $300 per kit depending on dose; GoodRx and manufacturer coupons reduce this considerably. The FDA Drug Approval Database lists all approved alprostadil products by NDA number.

2. Specialty urology pharmacies. Several Virginia specialty pharmacies stock alprostadil in pre-filled, single-dose injection devices with patient training materials. These pharmacies often coordinate directly with telehealth platforms.

3. 503A compounding pharmacies. Virginia-licensed 503A compounding pharmacies can compound alprostadil in concentrations not commercially available, such as lower microdose formulations for neurogenic ED or combination products (alprostadil with papaverine or phentolamine, the "bimix" or "trimix" regimens). The FDA 503A compounding framework requires that compounds be prepared for individual patient prescriptions from a licensed prescriber. Virginia Board of Pharmacy oversight applies; compounded alprostadil may be shipped to Virginia patients provided the dispensing pharmacy holds a valid Virginia non-resident pharmacy permit or is located in-state.

Trimix (alprostadil plus papaverine plus phentolamine) is frequently compounded when standard alprostadil alone produces inadequate response. A 2017 study in the International Journal of Impotence Research found trimix produced satisfactory erections in 84% of men who had failed monotherapy alprostadil. Virginia providers may initiate trimix through a compounding pharmacy after documented alprostadil monotherapy failure.

Virginia Medicaid coverage and prior authorization

Virginia Medicaid (also called Medallion 4.0 for managed care enrollees) covers alprostadil for refractory erectile dysfunction with prior authorization. "Refractory" is defined operationally as documented failure or contraindication to at least two oral PDE5 inhibitors.

Prior authorization documentation typically required:

• Diagnosis of ED with ICD-10 code N52.x
• Trial and failure of sildenafil (Viagra) at a dose of at least 50 mg on at least three separate occasions
• Trial and failure of tadalafil (Cialis) at a dose of at least 10 mg on at least three separate occasions, or documented contraindication to PDE5 inhibitors
• Prescriber attestation that alprostadil is medically necessary
• Copy of the initial in-office titration note if injection form is prescribed

The Virginia Department of Medical Assistance Services (DMAS) Preferred Drug List updates quarterly. Practitioners should verify current PA criteria, since criteria change. Most PA approvals are issued within three to five business days; expedited review within 24 hours is available for clinically urgent cases under 42 CFR § 438.210.

Commercial insurance coverage varies widely. Many plans classify alprostadil as a "sexual dysfunction" medication and apply specific coverage exclusions or high cost-sharing. Patients with private insurance should request a benefits verification before the prescription is sent.

Transferring an existing alprostadil prescription to Virginia

Patients relocating to Virginia or switching providers face a straightforward process. Alprostadil is not a controlled substance, so Virginia law imposes no special transfer restrictions. The receiving Virginia pharmacy contacts the previous pharmacy by phone or electronic transfer; no DEA authorization is required.

Patients transferring from out-of-state telehealth providers must ensure their new prescriber holds a Virginia license. A prescription originally written by a provider without Virginia licensure is not legally valid at a Virginia pharmacy, per Va. Code Ann. § 54.1-3408. Most national telehealth platforms staff Virginia-licensed clinicians and can issue a new prescription after a brief review visit.

Compounded alprostadil (trimix or bimix) cannot be simply transferred; a new prescription from a Virginia-licensed provider to a Virginia-licensed compounding pharmacy is required for each refill.

Side effects and safety considerations specific to dosing in Virginia clinical practice

Priapism (erection lasting more than four hours) is the primary safety concern with alprostadil. The incidence reported in the original Linet trial was 1.0% of patients over a 6-month period 1. Virginia emergency rooms and urology departments are familiar with the treatment protocol: aspiration and phenylephrine irrigation per AUA priapism guideline 7.

Patients should be counseled to:

• Start at the lowest effective dose, 2.5 mcg for neurogenic etiology, 5 mcg for vasculogenic
• Wait at least 24 hours between injection doses
• Use no more than three injections per week and no more than one per day
• Go to the nearest Virginia ER immediately if erection persists beyond four hours

Penile pain affects approximately 10 to 11% of patients using intracavernosal alprostadil, as documented in a Cochrane review of PGE1 therapy (N=2,401) 8. Urethral burning affects roughly 35% of MUSE users in clinical trials 3. Both effects diminish with time and dose adjustment.

Hypotension can occur, particularly when alprostadil is combined with antihypertensives. The FDA Caverject prescribing information specifically warns against concurrent use with antihypertensive agents without blood pressure monitoring at initiation. Virginia clinicians using telehealth platforms should obtain a home blood pressure reading before the first prescription is dispensed.

Dosing schedule and titration protocol

Virginia urologists and telehealth providers generally follow the manufacturer titration schedule, which aligns with AUA guidance on injection therapy 4:

| Etiology | Starting dose | Titration increment | Maximum dose | |---|---|---|---| | Neurogenic or psychogenic ED | 1.25 mcg | 1.25 mcg per visit | 60 mcg | | Vasculogenic or mixed ED | 2.5 mcg | 2.5 to 5 mcg per visit | 60 mcg |

The goal is the lowest dose producing a firm erection lasting 30 to 60 minutes without priapism. Most patients find their effective dose between 5 mcg and 20 mcg. Dose titration visits typically occur one to two weeks apart; telehealth providers may conduct follow-up visits via video once the patient has the injection technique confirmed in person.

For MUSE, the prescribing information recommends starting at 250 mcg and titrating in a clinic to the lowest effective dose before home use. Available doses are 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg.

Cost and access without insurance in Virginia

Without insurance, branded Caverject Impulse 10 mcg dual-chamber kits retail at approximately $90 to $130 each at major Virginia pharmacy chains. Generic alprostadil injection (as alprostadil alfadex) is available for $20 to $50 per dose through discount programs. MUSE 500 mcg suppositories run approximately $80 to $120 per six-pack.

Compounded trimix from Virginia 503A pharmacies typically costs $80 to $150 for a 5 mL multi-dose vial, representing substantially lower per-dose cost than commercial alprostadil when a patient requires higher doses. The FDA's information on drug pricing and compounding access clarifies that compounded products cannot claim equivalence to FDA-approved drugs but are legally dispensed under a valid prescription.

The Pfizer Patient Assistance Program covers Caverject for eligible uninsured patients. Applications are available through the NeedyMeds database and require income documentation.

As of the 2024 Endocrine Society Annual Meeting, Dr. Bradley Anawalt (University of Washington), one of the authors of the Endocrine Society's male hypogonadism guidelines, stated: "Cost is the most common reason men abandon injectable ED therapy. Compounded trimix from a reputable 503A pharmacy is a clinically reasonable, cost-effective alternative when commercial alprostadil is unaffordable." 9